Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study

Abstract

Rationale

The utility of patent foramen ovale (PFO) closure for secondary prevention in patients with prior cryptogenic stroke is uncertain despite multiple randomized trials completed to date.

Aims

The Gore REDUCE Clinical Study (REDUCE) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.

Methods and design

This controlled, open-label trial randomized 664 subjects with cryptogenic stroke at 63 multinational sites in a 2:1 ratio to either antiplatelet therapy plus patent foramen ovale closure (with GORE® HELEX® Septal Occluder or GORE® CARDIOFORM Septal Occluder) or antiplatelet therapy alone. Subjects will be prospectively followed for up to five years. Neuroimaging is required for all subjects at baseline and at two years or study exit.

Study outcomes

The two co-primary endpoints for the study are freedom from recurrent clinical ischemic stroke through at least 24 months post-randomization and incidence of new brain infarct (defined as clinical ischemic stroke or silent brain infarct) through 24 months. The primary analyses are an unadjusted log-rank test and a binomial test of subject-based proportions, respectively, both on the intent-to-treat population, with adjustment for testing multiplicity.

Discussion

The REDUCE trial aims to target a patient population with truly cryptogenic strokes. Medical therapy is limited to antiplatelet agents in both arms thereby reducing confounding. The trial should determine whether patent foramen ovale closure with the Gore septal occluders is safe and more effective than medical therapy alone for the prevention of recurrent clinical ischemic stroke or new silent brain infarct; the neuroimaging data will provide an opportunity to further support the proof of concept. The main results are anticipated in 2017.

Registration

Clinical trial registration-URL: http://clinicaltrials.gov/show/NCT00738894

Keywords

Patent foramen ovale cryptogenic stroke randomized trial percutaneous closure right-to-left shunt

Get full access to this article

View all access options for this article.

References

Bernick

Kuller

Dulberg

et al.

Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology 2001; 57: 1222–1229.

Lopez

Jagust

Dulberg

et al.

Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol 2003; 60: 1394–1399.

Putaala

Haapaniemi

Kurkinen

Salonen

Kaste

Tatlisumak

. Silent brain infarcts, leukoaraiosis, and long-term prognosis in young ischemic stroke patients. Neurology 2011; 76: 1742–1749.

Vermeer

Hollander

van Dijk

et al.

Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003; 34: 1126–1129.

Vermeer

Prins

den Heijer

Hofman

Koudstaal

Breteler

. Silent brain infarcts and the risk of dementia and cognitive decline. New Engl J Med 2003; 348: 1215–1222.

Overell

Bone

Lees

. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000; 55: 1172–1179.

Huang

Shao

. Differential lesion patterns on T2-weighted magnetic resonance imaging and fluid-attenuated inversion recovery sequences in cryptogenic stroke patients with patent foramen ovale. J Stroke Cerebrovasc Dis 2014; 23: 1690–1695.

Kim

Choi

Kim

et al.

Juxtacortical spots on fluid-attenuated inversion recovery images in cryptogenic transient ischemic attack. J Clin Neurol 2013; 9: 103–110.

Liu

Plotz

Rohr

Stingele

Jansen

Alfke

. Association of right-to-left shunt with frontal white matter lesions in T2-weighted MR imaging of stroke patients. Neuroradiology 2009; 51: 299–304.

10.

Agarwal

Bajaj

Kumbhani

Tuzcu

Kapadia

. Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism. JACC Cardiovasc Interv 2012; 5: 777–789.

11.

Kitsios

Dahabreh

Abu Dabrh

Thaler

Kent

. Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke 2012; 43: 422–431.

12.

Vigna

Inchingolo

Giannatempo

et al.

Clinical and brain magnetic resonance imaging follow-up after percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. Am J Cardiol 2008; 101: 1051–1055.

13.

Carroll

Saver

Thaler

et al.

Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New Engl J Med 2013; 368: 1092–1100.

14.

Furlan

Reisman

Massaro

et al.

Closure or medical therapy for cryptogenic stroke with patent foramen ovale. New Engl J Med 2012; 366: 991–999.

15.

Meier

Kalesan

Mattle

et al.

Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England J Med 2013; 368: 1083–1091.

16.

Kent

Dahabreh

Ruthazer

et al.

Device closure of patent foramen ovale after stroke: pooled analysis of completed randomized trials. J Am Coll Cardiol 2016; 67: 907–917.

17.

Billinger

Ostermayer

Carminati

et al.

HELEX Septal Occluder for transcatheter closure of patent foramen ovale: multicentre experience. EuroIntervention 2006; 1: 465–471.

18.

Butera

Saracino

Danna

Sganzerla

Chessa

Carminati

. Transcatheter PFO closure with GORE((R)) septal occluder: early and mid-term clinical results. Catheter Cardiovasc Interv 2013; 82: 944–949.

19.

Thomson

Hildick-Smith

Clift

et al.

Patent foramen ovale closure with the Gore septal occluder: initial UK experience. Catheter Cardiovasc Interv 2014; 83: 467–473.

20.

Zhu

Dufouil

Tzourio

Chabriat

. Silent brain infarcts: a review of MRI diagnostic criteria. Stroke 2011; 42: 1140–1145.

21.

Khairy

O’Donnell

Landzberg

. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med 2003; 139: 753–760.

22.

Mas

Arquizan

Lamy

et al.

Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. New Engl J Med 2001; 345: 1740–1746.

23.

Sacco

Kasner

Broderick

et al.

An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 2064–2089.

24.

Sankoh

Huque

Dubey

. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med 1997; 16: 2529–2542.

25.

Mas

Derumeaux

Amarenco

et al.

Close: Closure of patent foramen ovale, oral anticoagulants or antiplatelet therapy to prevent stroke recurrence: study design. Int J Stroke 2016; 11: 724–732.

26.

Khattab

Windecker

Juni

et al.

Randomized clinical trial comparing percutaneous closure of patent foramen ovale (PFO) using the Amplatzer PFO Occluder with medical treatment in patients with cryptogenic embolism (PC-Trial): rationale and design. Trials 2011; 12: 56.

27.

Furlan

Reisman

Massaro

et al.

Study design of the CLOSURE I Trial: a prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the STARFlex septal closure system versus best medical therapy in patients with stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale. Stroke 2010; 41: 2872–2883.

28.

European Stroke Organisation Executive C, Committee ESOW. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457–507.

29.

Furie

Kasner

Adams

et al.

Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42: 227–276.

30.

Messe SR, Gronseth G, Kent DM, et al. Practice advisory: recurrent stroke with patent foramen ovale (update of practice parameter). Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2016; 87: 815–821.

31.

Thaler

Ruthazer

Weimar

et al.

Recurrent stroke predictors differ in medically treated patients with pathogenic vs. other PFOs. Neurology 2014; 83: 221–226.

32.

Meller

Baumbach

Brickman

Lansky

. Clinical implications for diffusion-weighted MRI brain lesions associated with transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2014; 83: 502–508.

33.

Stackhouse

Goel

Qureshi

et al.

Off-label closure during CLOSURE study. J Invasive Cardiol 2012; 24: 608–611.

34.

Brief Summary of the Circulatory System Devices Panel Meeting – May 24, 2016. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM503562.pdf (2016, accessed 9 March 2017).